Drug Monograph
Sumatriptan
sumatriptan succinate · Brand: Imitrex
Pharmacokinetic Profile
Half-Life
~2.5 hours
Metabolism
MAO-A (primary)
Protein Binding
14–21%
Bioavailability
~15% oral; ~97% SC
Volume of Distribution
2.4 L/kg (~170 L)
Clinical Information
Drug Class
Triptan (5-HT1B/1D agonist)
Available Doses
Oral: 25, 50, 100 mg; SC: 4, 6 mg; Nasal: 5, 10, 20 mg
Route
Oral, Subcutaneous, Intranasal
Renal Adjustment
Not studied; likely not needed
Hepatic Adjustment
Oral max 50 mg (mild-mod); CI in severe
Pregnancy
Caution — animal data suggest fetal harm
Lactation
Excreted in milk; avoid feeding for 12 h post-dose
Schedule
Prescription only (not a controlled substance)
Generic Available
Yes (all formulations)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Acute migraine with or without aura | Adults (≥18 years) | Acute abortive (all formulations) | FDA Approved |
| Acute cluster headache | Adults (≥18 years) | Acute abortive (subcutaneous only) | FDA Approved |
Sumatriptan was the first triptan approved for clinical use (1992) and remains one of the most widely prescribed acute migraine treatments worldwide. The American Headache Society recommends sumatriptan as a first-line option for moderate-to-severe migraine attacks (AHS 2019). It is not indicated for migraine prophylaxis. For cluster headache, only the subcutaneous formulation carries FDA approval; oral and intranasal forms are not labelled for this use.
Off-Label Uses
Post-dural puncture headache (PDPH): Limited case series suggest benefit with SC or oral sumatriptan; evidence quality is low.
Cyclic vomiting syndrome: Small uncontrolled series report symptom reduction with intranasal or SC sumatriptan in adults; evidence quality is low.
Trigeminal neuralgia (adjunctive): Two small RCTs found SC sumatriptan 3 mg provided meaningful pain relief as adjunct therapy; evidence quality is moderate.
Dosing
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Migraine — mild-to-moderate attack, oral route preferred | 25 mg PO | 25–50 mg PO | 200 mg/24 h | May repeat ≥2 h after first dose if partial response 50 mg generally preferred starting dose for most patients |
| Migraine — moderate-to-severe attack, oral route | 50–100 mg PO | 50–100 mg PO | 200 mg/24 h | 100 mg may not add efficacy over 50 mg but increases side effects Only redose if some response to first dose |
| Migraine — nausea/vomiting prominent or rapid relief needed | 6 mg SC | 6 mg SC | 12 mg/24 h | Onset within 10 min; may repeat ≥1 h after first injection 4 mg SC available if 6 mg causes dose-limiting side effects |
| Migraine — intranasal route (alternative non-oral) | 20 mg IN | 5–20 mg IN | 40 mg/24 h | Single spray in one nostril; may repeat ≥2 h 10 mg dose = one 5 mg spray per nostril |
| Acute cluster headache | 6 mg SC | 6 mg SC | 12 mg/24 h | SC route only for this indication; may repeat ≥1 h Lower doses not studied for efficacy in cluster headache |
| Post-SC injection oral follow-on | 25–100 mg PO | 25–100 mg PO | 100 mg oral/24 h | For recurrence after initial SC response; ≥2 h between oral doses |
Special Population Adjustments
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Mild-to-moderate hepatic impairment (oral) | 25 mg PO | 25–50 mg PO | 50 mg single dose | AUC and Cmax increase ~70% in moderate impairment SC does not require adjustment in mild-mod impairment |
| Severe hepatic impairment | Contraindicated — all oral formulations | Not studied; presystemic clearance is hepatic | ||
| Elderly patients | 25–50 mg PO | 25–50 mg PO | 200 mg/24 h | Assess cardiovascular risk before prescribing No PK differences observed in elderly, but cardiac risk is higher |
Clinical Pearl: Choosing the Right Dose
The 50 mg oral tablet is the most commonly used starting dose in clinical practice. Controlled trials demonstrate similar efficacy to 100 mg with fewer adverse effects. The 25 mg dose is appropriate for patients who are triptan-naive or who have experienced side effects with higher doses. Reserve the 100 mg dose for patients with documented incomplete response to 50 mg.
Pharmacology
Mechanism of Action
Sumatriptan is a selective agonist at serotonin 5-HT1B and 5-HT1D receptors, with additional activity at 5-HT1F receptors. Its therapeutic action in migraine is attributed to two complementary mechanisms. First, activation of 5-HT1B receptors on intracranial blood vessels produces vasoconstriction of the dilated meningeal arteries that contribute to migraine pain. Second, agonism at 5-HT1D receptors on trigeminal nerve terminals inhibits the release of vasoactive neuropeptides, including calcitonin gene-related peptide (CGRP) and substance P, reducing neurogenic inflammation and pain signal transmission to the trigeminal nucleus caudalis. Together, these actions halt the cascade of vascular and neuroinflammatory events underlying the acute migraine attack.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral bioavailability ~15%; Tmax ~2 h (oral), ~12 min (SC); SC bioavailability ~97% | Low oral bioavailability due to extensive first-pass metabolism; SC offers fastest onset; food has minimal effect on absorption |
| Distribution | Vd ~2.4 L/kg (~170 L); protein binding 14–21% | Wide tissue distribution; low protein binding means minimal displacement interactions; limited but clinically relevant CNS penetration |
| Metabolism | Primarily MAO-A to inactive indole acetic acid (IAA) metabolite; minor CYP-mediated pathways | MAO-A inhibitors increase exposure 7-fold (oral) or 2-fold (SC) — combination is contraindicated; MAO-B inhibitors do not affect metabolism |
| Elimination | t½ ~2.5 h; 60% renal (mostly as IAA), 40% fecal; only 3% excreted unchanged | Short half-life allows headache recurrence in 25–40% of patients; renal impairment unlikely to affect clearance significantly |
Side Effects
Adverse reaction data below reflect oral sumatriptan tablet trials unless otherwise noted. The SC injection formulation has higher overall adverse event rates, particularly injection site reactions. Incidence rates are drawn from pooled placebo-controlled clinical trial data in the FDA prescribing information.
≥10%
Very Common (SC injection formulation)
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Injection site reaction (pain, erythema) | 59% (vs 24% placebo) | Usually mild and transient; resolves within 60 min |
| Tingling/paresthesia | 14% (vs 3% placebo) | Dose-related; typically involves extremities and face |
| Warm/hot sensation | 11% (vs 4% placebo) | Transient; usually peaks within 15 min of injection |
| Dizziness/vertigo | 12% (vs 4% placebo) | Advise against driving or operating machinery immediately after dosing |
1–10%
Common (Oral Tablets — Pooled Trials)
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Pain and pressure sensations (various sites) | 6–8% (vs 4% placebo) | Includes chest, throat, jaw, and limb sensations; usually non-cardiac in origin |
| Atypical sensations (paresthesia, warm/cold) | 5–6% (vs 4% placebo) | Typically brief and self-limiting; higher incidence with 100 mg |
| Chest pain/tightness/pressure | 1–2% (vs 1% placebo) | Non-ischemic in most patients; evaluate if cardiac risk factors present |
| Neck/throat/jaw pain/tightness | 2–3% (vs <1% placebo) | Commonly described as pressure sensation; dose-related |
| Malaise/fatigue | 2–3% (vs <1% placebo) | Usually transient; may overlap with post-migraine fatigue |
| Vertigo | ≤2% (vs <1% placebo) | More pronounced with 100 mg dose |
| Flushing | 7% (SC only; vs 2% placebo) | Brief and self-limiting; related to vasoactive properties |
| Nausea/vomiting | 4% (SC, cluster HA trials; vs 0% placebo) | May be difficult to distinguish from migraine-associated nausea |
Serious
Serious (Regardless of Frequency)
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Myocardial ischemia / infarction | Very rare | Within hours of dose | Discontinue permanently; emergency cardiac evaluation and treatment |
| Coronary artery vasospasm (Prinzmetal-type) | Very rare | Minutes to hours | Discontinue permanently; cardiac monitoring; contraindicated if recurs |
| Cardiac arrhythmias (VT/VF) | Very rare | Within hours of dose | Emergency resuscitation; permanent discontinuation |
| Cerebrovascular events (stroke, hemorrhage) | Very rare | Variable | Discontinue immediately; neurological assessment; some cases were primary stroke misdiagnosed as migraine |
| Serotonin syndrome | Rare | Minutes to hours (with serotonergic co-administration) | Discontinue all serotonergic agents; supportive care; cyproheptadine if severe |
| Anaphylaxis / anaphylactoid reactions | Very rare | Any time | Emergency treatment; permanent contraindication to sumatriptan |
| Peripheral vasospasm (GI ischemia, Raynaud syndrome, splenic infarction) | Very rare | Hours post-dose | Discontinue; rule out vasospastic reaction before retreatment |
| Seizures | Very rare | Variable | Discontinue; use with caution in patients with epilepsy or lowered seizure threshold |
| Medication overuse headache | Frequency increases with ≥10 days/month use | Weeks to months of regular use | Withdrawal and detoxification; transition to preventive therapy |
Discontinuation
Discontinuation Rates
Clinical Practice (Oral)
~25% over long-term use
Top reasons: Headache recurrence, insufficient relief, chest symptoms, adverse effects
SC Injection
~10% due to chest symptoms
Top reasons: Chest symptoms (10%), injection site discomfort, headache recurrence
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Headache recurrence | Primary reason | Recurrence in 25–40% of attacks due to short half-life; second dose often effective |
| Chest symptoms | Up to 10% (SC) | Usually non-cardiac; warn patients in advance to reduce anxiety-driven discontinuation |
| Insufficient headache relief | Variable | More common with oral 25 mg dose and late treatment timing |
| Adverse effects (fatigue, dizziness) | Variable | Dose-dependent; consider dose reduction before full discontinuation |
Managing Chest Symptoms
Chest pressure, tightness, and pain are commonly reported after sumatriptan, particularly with the SC formulation. In the vast majority of cases, these sensations are non-cardiac in origin and related to the drug’s vasoconstrictive activity on non-coronary vascular beds. However, in patients with cardiovascular risk factors, a cardiac evaluation should be performed before attributing these symptoms to a benign triptan effect. Proactive counselling about the expected nature of these sensations significantly reduces unnecessary emergency department visits and patient discontinuation.
Drug Interactions
Sumatriptan is primarily metabolized by monoamine oxidase A (MAO-A), with minor contributions from cytochrome P450 enzymes. It does not significantly inhibit or induce hepatic CYP isoenzymes, resulting in a relatively narrow but clinically important interaction profile centered on serotonergic pathways and vasospastic potential.
Major
MAO-A Inhibitors (e.g., moclobemide, phenelzine)
MechanismMAO-A inhibition reduces sumatriptan metabolism
EffectOral sumatriptan systemic exposure increased ~7-fold; SC exposure doubled
ManagementContraindicated — do not use sumatriptan during or within 2 weeks of MAO-A inhibitor use
FDA PI
Major
Ergotamine / Dihydroergotamine
MechanismAdditive vasospastic effects via serotonin receptor agonism
EffectProlonged vasospasm and potential ischemia
ManagementContraindicated within 24 hours of each other in either direction
FDA PI
Major
Other Triptans (e.g., rizatriptan, zolmitriptan)
MechanismAdditive 5-HT1B/1D receptor agonism
EffectPotential cumulative vasospasm
ManagementDo not use different triptans within 24 hours of each other
FDA PI
Moderate
SSRIs / SNRIs (e.g., fluoxetine, venlafaxine)
MechanismCombined serotonergic activity raises serotonin syndrome risk
EffectPotential for serotonin syndrome (agitation, hyperthermia, hyperreflexia, clonus)
ManagementCombination is used frequently in practice; monitor for serotonin syndrome symptoms, especially at initiation or dose changes
FDA PI / AHS
Moderate
Tricyclic Antidepressants (e.g., amitriptyline)
MechanismSerotonin reuptake inhibition combined with 5-HT agonism
EffectIncreased serotonin syndrome risk
ManagementCaution; monitor for serotonergic toxicity; commonly co-prescribed for migraine prophylaxis
FDA PI
Minor
St John’s Wort (Hypericum perforatum)
MechanismSerotonin reuptake inhibition by hypericin/hyperforin
EffectIncreased serotonergic effects
ManagementAdvise patients to stop St John’s Wort if sumatriptan therapy is necessary
BNF / Case Reports
Minor
Propranolol / Flunarizine / Pizotifen
MechanismNo significant pharmacokinetic interaction identified
EffectNo change in sumatriptan levels or clinical effect
ManagementSafe to combine; migraine prophylactic agents do not require dose adjustment
PK Study
Minor
Alcohol
MechanismNo pharmacokinetic interaction
EffectAlcohol does not alter sumatriptan levels
ManagementNo specific restriction, though alcohol may be a migraine trigger in some patients
PK StudyMonitoring
-
Cardiovascular Assessment
Before first dose
Routine Perform cardiovascular evaluation in triptan-naive patients with multiple risk factors (age, smoking, diabetes, hypertension, obesity, family history). Consider initial dose in a medically supervised setting with ECG if risk factors are present. -
Blood Pressure
Each clinical visit
Routine Monitor for transient blood pressure elevation. Sumatriptan is contraindicated in uncontrolled hypertension. Hypertensive crisis has been reported on rare occasions. -
Headache Frequency
Monthly diary
Routine Track frequency of acute medication use. Using triptans ≥10 days per month risks medication overuse headache. Safety of treating >4 headaches per month is not established. -
Hepatic Function
Baseline (if indicated)
Trigger-based Assess liver function if hepatic disease is suspected. Oral bioavailability increases markedly in hepatic impairment. Severe hepatic impairment is a contraindication. -
Serotonin Syndrome Signs
Each use with serotonergic drugs
Trigger-based Watch for agitation, hyperthermia, hyperreflexia, clonus, tremor, and autonomic instability when sumatriptan is co-administered with SSRIs, SNRIs, TCAs, or other serotonergic agents. -
Cardiac Symptoms
Any new symptom
Trigger-based If chest pain, shortness of breath, or palpitations occur, evaluate for cardiac ischemia before allowing continued use. Most chest symptoms are non-cardiac, but formal evaluation is warranted for new or concerning presentations. -
Periodic CV Evaluation
Periodically in long-term users
Routine For intermittent long-term users with cardiovascular risk factors, periodic cardiovascular re-evaluation is recommended by the FDA prescribing information.
Contraindications & Cautions
Absolute Contraindications
- Ischemic coronary artery disease (angina, documented MI, silent ischemia) or coronary artery vasospasm (Prinzmetal angina)
- Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders
- History of stroke or TIA, or history of hemiplegic or basilar migraine
- Peripheral vascular disease
- Ischemic bowel disease
- Uncontrolled hypertension
- Severe hepatic impairment (oral formulations)
- Use of another triptan or ergotamine within 24 hours
- Concurrent or recent MAO-A inhibitor use (within 2 weeks)
- Known hypersensitivity to sumatriptan (anaphylaxis or angioedema previously)
Relative Contraindications (Specialist Input Recommended)
- Multiple cardiovascular risk factors (diabetes, smoking, obesity, strong family CAD history, post-menopausal women, men >40) — requires cardiac evaluation before first dose and periodic reassessment
- Controlled hypertension — transient BP elevations may occur; monitor closely
- Mild-to-moderate hepatic impairment — oral dose capped at 50 mg; consider SC formulation if full dose needed
- History of seizures or conditions lowering seizure threshold — rare seizure reports exist
Use with Caution
- Concurrent SSRI/SNRI/TCA therapy — serotonin syndrome risk (low but real); monitor at each use
- Sulfonamide allergy — limited evidence of cross-sensitivity; use with caution
- Pregnancy — animal studies show embryolethality at high doses; registry data do not suggest increased teratogenicity, but weigh risks and benefits individually
- High-frequency use (≥10 days/month) — medication overuse headache risk; limit to <10 days per month
FDA Class-Wide Regulatory Warning
Cardiovascular Risk with Triptans
Serious cardiac events, including myocardial infarction, have been reported following the use of 5-HT1 agonists. Some events have occurred in patients without known cardiovascular disease. Perform cardiovascular evaluation in patients with multiple risk factors before administering sumatriptan. Consider administering the first dose in a medically supervised setting with immediate post-dose ECG in higher-risk patients.
Patient Counselling
Purpose of Therapy
Sumatriptan is a targeted rescue medication that works to stop a migraine or cluster headache that has already started. It is not a painkiller and does not prevent future attacks. For best results, it should be taken as early as possible after headache onset. It works by narrowing widened blood vessels in the brain and reducing inflammation around pain-sensing nerves.
How to Take
For oral tablets, swallow whole with water. The medication can be taken with or without food. If the first dose provides partial or complete relief but the headache returns, a second dose can be taken at least 2 hours after the first. If the first dose provides no relief at all, do not take a second dose for the same attack without consulting a prescriber. Do not use on more than approximately 9 days per month to avoid medication overuse headache.
Chest, Throat, or Jaw Tightness
Tell patient
A sensation of tightness, heaviness, or pressure in the chest, throat, or jaw is a commonly reported effect and is usually not related to the heart. It typically lasts less than 30 minutes and resolves on its own. Knowing to expect this sensation can prevent unnecessary alarm.
Call prescriber
If the chest sensation is severe, persistent, accompanied by shortness of breath, left arm pain, or an irregular heartbeat, seek emergency medical attention immediately.
Drowsiness and Dizziness
Tell patient
Sumatriptan can cause drowsiness, dizziness, and fatigue. These effects are usually mild and brief. Avoid driving or operating machinery until you know how the medication affects you.
Call prescriber
If dizziness is severe, persistent, or accompanied by confusion, weakness, or slurred speech, seek urgent medical evaluation to rule out a neurological event.
Tingling and Warm Sensations
Tell patient
Tingling, numbness, or sensations of warmth or flushing may occur, particularly in the face and hands. These are expected pharmacological effects and typically resolve within an hour.
Call prescriber
If tingling is accompanied by weakness on one side of the body, visual changes, or difficulty speaking, seek emergency care.
Headache Recurrence
Tell patient
Because sumatriptan is cleared from the body quickly (half-life about 2.5 hours), the headache may return in 25–40% of treated attacks. A second dose can be taken at least 2 hours after the first if the initial dose provided some benefit.
Call prescriber
If migraines consistently recur after sumatriptan or if you find yourself using it more than 9 days per month, discuss preventive therapy options with your prescriber.
Medication Overuse Headache
Tell patient
Using any acute migraine treatment too frequently (≥10 days per month) can paradoxically worsen headaches over time. Keep a headache diary to track usage days per month.
Call prescriber
If your headaches are becoming more frequent or you are relying on sumatriptan multiple times per week, contact your prescriber to discuss preventive strategies.
Serotonin Syndrome Risk
Tell patient
If you also take an antidepressant (SSRI, SNRI, or TCA), be aware of the small risk of serotonin syndrome. Symptoms include agitation, rapid heartbeat, high body temperature, muscle twitching, and confusion.
Call prescriber
If you develop a combination of agitation, sweating, rapid pulse, confusion, or involuntary muscle movements after taking sumatriptan with an antidepressant, seek emergency care.
Sources
Regulatory (PI / SmPC)
- Sumatriptan Tablets USP — Full Prescribing Information. Revised February 2026. drugs.com/pro/sumatriptan Current FDA-approved prescribing information for oral sumatriptan tablets; primary source for dosing, contraindications, and adverse reaction data.
- IMITREX (sumatriptan) Injection — Full Prescribing Information. GlaxoSmithKline. Revised 2021. FDA Label (PDF) FDA label for SC injection formulation; source for cluster headache dosing, injection-specific adverse events, and pregnancy registry data.
- IMITREX (sumatriptan succinate) Tablets — Full Prescribing Information. GlaxoSmithKline. Revised 2024. GSK PI (PDF) Brand-name prescribing information with detailed pharmacokinetic parameters and hepatic impairment data.
Key Clinical Trials
- Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache. 1998;38(3):184-190. doi:10.1046/j.1526-4610.1998.3803184.x Large multinational dose-ranging trial (N=1003) establishing that 50 mg provides similar efficacy to 100 mg with fewer adverse events.
- The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med. 1991;325(5):316-321. doi:10.1056/NEJM199108013250504 Landmark RCT establishing subcutaneous sumatriptan 6 mg efficacy, demonstrating headache relief in 70% of patients within 1 hour.
Guidelines
- Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3-20. doi:10.1111/head.12499 AHS systematic review establishing Level A evidence for oral and SC sumatriptan in acute migraine treatment.
- Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia. 1998;18(8):532-538. doi:10.1046/j.1468-2982.1998.1808532.x Systematic review of 30 RCTs comparing NNT across sumatriptan formulations; SC had highest efficacy (NNT ~2.0).
Mechanistic / Basic Science
- Humphrey PPA, Feniuk W, Perren MJ, et al. Serotonin and migraine. Ann N Y Acad Sci. 1990;600:587-598. doi:10.1111/j.1749-6632.1990.tb16912.x Foundational work on sumatriptan’s mechanism as a selective 5-HT1 agonist with cranial vascular selectivity.
- Goadsby PJ, Lipton RB, Ferrari MD. Migraine — current understanding and treatment. N Engl J Med. 2002;346(4):257-270. doi:10.1056/NEJMra010917 Authoritative review of CGRP’s role in migraine pathophysiology and the mechanism by which triptans inhibit neuropeptide release from trigeminal nerve terminals.
Pharmacokinetics / Special Populations
- Duquesnoy C, Mamet JP, Sumner D, Fuseau E. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur J Pharm Sci. 1998;6(2):99-104. doi:10.1016/S0928-0987(97)00073-0 Comparative PK study across all sumatriptan formulations; confirms 15% oral and 97% SC bioavailability.
- Scott AK. Sumatriptan clinical pharmacokinetics. Clin Pharmacokinet. 1994;27(5):337-344. doi:10.2165/00003088-199427050-00002 Comprehensive PK review establishing key parameters: Vd 170L, protein binding <21%, t½ ~2 hours, MAO-A-dependent metabolism.
- Brar YS, Hosseini SA, Saadabadi A. Sumatriptan. In: StatPearls. Treasure Island, FL: StatPearls Publishing; updated November 12, 2023. NCBI Bookshelf Comprehensive clinical pharmacology overview including special population considerations and updated safety data.
- Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22(8):633-658. doi:10.1046/j.1468-2982.2002.00404.x Definitive meta-analysis comparing all triptans; positions sumatriptan 50 mg as the clinical and economic benchmark for oral triptan therapy.